To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesions

To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesions in women with ovarian endometriosis: a randomized, double-blind placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150905023897N5

Enrollment

Registered

2020-02-04

Start date

2020-02-07

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrioma lesions. Endometriosis of ovary

Interventions

Intervention 1: Intervention group: People in the intervention group receive Liverpool 140 mg tablets at the pharmaceutical company twice daily for three months. Intervention 2: Control group: People

Eligibility

Sex/Gender

Female

Age

15 Years to 49 Years

Inclusion criteria

Inclusion criteria: Iranian married women of reproductive age (15-49) No chronic disease (diabetes, hypertension, liver and kidney disease, previous venous embolism ...) based on medical records Women with a confirmed diagnosis of ovarian endometriosis via transvaginal ultrasonography performed by a single sonologist and CA125 level People are willing to participate in the study

Exclusion criteria

Exclusion criteria: participants suffering from the side effects of silymarin Individuals unwilling to continue participating in the study Failure to comply with treatment protocol Taking specific medications such as anti-depressant, GnRH analogues, systemic glucocorticoids, or other milk thistle products and anti-inflammatory supplements with a specified wash-out period for each one

Design outcomes

Primary

Measure	Time frame
Interleukin 6 levels. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: Using the ELISA method in pg / ml.;Endometrial lesion volume measurement. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: ultrasound or laparoscopy in millimeters.;Sexual function. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: Using the FSFI questionnaire.;Quality of Life. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: Using the SF-12 questionnaire.;Pelvic pain. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: VAS visual analog scale.	—

Measure

Time frame

Interleukin 6 levels. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: Using the ELISA method in pg / ml.;Endometrial lesion volume measurement. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: ultrasound or laparoscopy in millimeters.;Sexual function. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: Using the FSFI questionnaire.;Quality of Life. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: Using the SF-12 questionnaire.;Pelvic pain. Timepoint: At the beginning of the study and three months after starting the Livergol pill. Method of measurement: VAS visual analog scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahideh Jahanian Sadatmahalleh

Tarbiat modares University

Shahideh.jahanian@modares.ac.ir+98 21 2230 6480

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026